Efficacy of racotumomab or nimotuzumab vs docetaxel as second-line therapy for advanced non-small cell lung cancer patients

被引：0
|
作者：
Hernandez, M. [1 ]
Neninger, E. [2 ]
Santiesteban, E. [3 ]
Camacho, K. [3 ]
Hernandez, N. [4 ]
Amador, R. [5 ]
Acosta, S. [6 ]
Gonzalez, Y. [7 ]
Jimenez, Y. [8 ]
Corella, M. [9 ]
Ortiz, R. A. [10 ]
Bello, L. [11 ]
Calana, A. [12 ]
Pichs, G. [13 ]
Cala, M. [14 ]
Flores, Y. [15 ]
Viada, C. [16 ]
Robaina, M. [17 ]
Crombet, T. [1 ]
机构：
[1] Ctr Mol Immunol, Clin Res, Havana, Cuba
[2] Hosp Clin Quirurg Hermanos Ameijeiras, Clin Oncol, Havana, Cuba
[3] Jose R Lopez Tabranes Hosp, Clin Oncol, Matanzas, Cuba
[4] Miguel Enriquez Hosp, Clin Oncol, Havana, Cuba
[5] III Congreso Hosp, Clin Oncol, Pinar Del Rio, Cuba
[6] Saturnino Lora Hosp, Clin Oncol, Santiago De Cuba, Cuba
[7] Comandante Pinares Hosp, Clin Oncol, Artemisa, Cuba
[8] Camilo Cienfuegos Hosp, Clin Oncol, Sancti Spiritus, Cuba
[9] Vladimir I Lenin Hosp, Clin Oncol, Holguin, Cuba
[10] Celestino Hernandez Hosp, Clin Oncol, Villa Clara, Cuba
[11] Antonio Luaces Iraola Hosp, Clin Oncol, Ciego De Avila, Cuba
[12] Gustavo Aldereguia Lima Hosp, Clin Oncol, Cienfuegos, Cuba
[13] Celia Sanchez Manduley Hosp, Clin Oncol, Granma, Cuba
[14] Juan Bruno Zayas Hosp, Clin Oncol, Santiago De Cuba, Cuba
[15] Natl Inst Oncol & Radiobiol, Clin Oncol, Havana, Cuba
[16] Ctr Mol Immunol, Clin Res, Havana, Cuba
[17] Natl Coordinating Ctr Clin Trials, Clin Res, Havana, Cuba
来源：
ANNALS OF ONCOLOGY | 2018年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1164P
引用
收藏
页码：415 / 415
页数：1
相关论文
共 50 条
  • [1] Docetaxel as Second-line Monotherapy for Advanced Non-small Cell Lung Cancer
    Kang, Hyun Mo
    Lee, Jeong Eun
    Jang, Pil Soon
    Lee, Yun Sun
    Kwon, Sun Jung
    An, Jin Young
    Jung, Sung Soo
    Kim, Ju Ock
    Kim, Sun Young
    [J]. TUBERCULOSIS AND RESPIRATORY DISEASES, 2005, 58 (05) : 465 - 472
  • [2] Weekly docetaxel and vinorelbine as second-line therapy in advanced non-small cell lung cancer
    Huber, R
    Schmidt, M
    Borgmeier, A
    [J]. LUNG CANCER, 2005, 49 : S248 - S248
  • [3] Racotumomab in Non-Small Cell Lung Cancer as Maintenance and Second-Line Treatment
    Caceres-Lavernia, Haslen H.
    Neninger-Vinageras, Elia
    Varona-Rodriguez, Leslie M.
    Olivares-Romero, Yoli A.
    Sanchez-Rojas, Irlis
    Mazorra-Herrera, Zaima
    Basanta-Bergolla, Denenke
    Duvergel-Calderin, Dayanis
    Torres-Cuevas, Boris L.
    del Castillo-Carrillo, Concepcion
    [J]. MEDICC REVIEW, 2021, 23 (3-4) : 21 - 28
  • [4] SECOND-LINE THERAPY FOR ADVANCED NON-SMALL CELL LUNG CANCER
    Cullen, M.
    [J]. LUNG CANCER, 2009, 64 : S13 - S13
  • [5] Is irinotecan plus docetaxel useful as second-line therapy in advanced non-small cell lung cancer?
    Cortinovis, Diego
    Bidoli, Paolo
    Cullura, Daniela
    Lorusso, Vito
    Ardizzoia, Antonio
    Amoroso, Vito
    Bandera, Mauro
    Aitini, Enrico
    Fusi, Alberto
    Zilembo, Nicoletta
    Radula, Daniela
    Bajetta, Emilio
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2008, 3 (04) : 405 - 411
  • [6] Docetaxel and mitomycin as second-line treatment in advanced non-small cell lung cancer
    J. Feliu
    G. Martín
    J. Castro
    A. Sundlov
    A. Rodriguez-Jaráiz
    E. Casado
    M. Lomas
    C. Madroñal
    A. Galán
    C. Belda
    M. Gonzalez-Barón
    [J]. Cancer Chemotherapy and Pharmacology, 2006, 58 : 527 - 531
  • [7] Docetaxel and mitomycin as second-line treatment in advanced non-small cell lung cancer
    Feliu, J.
    Martin, G.
    Castro, J.
    Sundlov, A.
    Rodriguez-Jaraiz, A.
    Casado, E.
    Lomas, M.
    Madronal, C.
    Galan, A.
    Belda, C.
    Gonzalez-Baron, M.
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2006, 58 (04) : 527 - 531
  • [8] Efficacy and safety of second-line immunotherapy in patients with advanced non-small cell lung cancer
    Sanchez Escudero, Laura
    Cobelas Cartagena, Stephanie S.
    Sanchez Esperilla, Maria
    Bayo, Juan L.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [9] Weekly docetaxel as a second-line treatment for advanced non-small cell lung cancer (NSCLC).
    García, R
    Pérez, P
    Alfonso, R
    Pérez-Manga, G
    Díaz-Rubio, E
    [J]. ANNALS OF ONCOLOGY, 2000, 11 : 116 - 116
  • [10] Docetaxel and carboplatin as the second-line treatment of non-small cell lung cancer
    Pesek, M
    Holá, V
    [J]. LUNG CANCER: CURRENT TOPICS, 2001, : 155 - 160
12345